These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22322848)

  • 1. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
    Park SG; Chung CH; Park CY
    Tumori; 2011; 97(6):794-9. PubMed ID: 22322848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
    Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
    World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Chan SL; Lin CC; Chiorean EG; Holcombe RF; Mulcahy MF; Carter WD; Patel K; Wilson WR; Melink TJ; Gutheil JC; Tsao CJ
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):539-45. PubMed ID: 21594722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 7. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
    Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
    Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
    Frieling T; Heise J; Wassilew SW
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of variant angina in a patient under chronic treatment with sorafenib.
    Porto I; Leo A; Miele L; Pompili M; Landolfi R; Crea F
    Nat Rev Clin Oncol; 2010 Aug; 7(8):476-80. PubMed ID: 20479781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
    Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
    Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
    Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
    Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
    Wang SX; Byrnes A; Verma S; Pancoast JR; Rixe O
    Target Oncol; 2010 Mar; 5(1):59-63. PubMed ID: 20309643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.